retatrutide triple agonist obesity trial 🚨 HOT OFF THE PRESS: Phase 3 data has arrived — and the medicine world is paying attention. In Lilly's TRIUMPH-1 trial, participants receiving the highest dose achieved an average 🚨 Retatrutide TRIUMPH-1 Phase 3

doi: 10.1080/00207454.2021.1924707 108 HolstJJ

This is worth flagging because many clients establish a timing habit during escalation choosing morning or evening based on side effect management and then never revisit the decision once the protocol has stabilized

Discussion An increasing population of obese patients with nephrolithiasis is seeking weight loss through various surgical, dietary, and pharmacological therapies

Stay Hydrated: GLP-1s can reduce thirst, increasing the risk of dehydration

The new offering combines personalized microdoses of GLP-1 medication, regular at-home biomarker testing, and Noom's digital healthy habits platform to empower people with data, insights, personalized action plans, and the motivational support to take control of their long-term wellbeing

Coetzee and me, develop personalized nutritional protocols